Top Story Today
Lilly Bets $2.3 Billion on a Blood Cancer Drug That Hasn't Been Tested in a Single Human
Eli Lilly is acquiring Ajax Therapeutics for up to $2.3 billion in cash, and the lead drug hasn't produced one data point in humans. The target is myelofibrosis, a rare blood cancer where current treatments manage symptoms but don't change the disease's trajectory. What makes this different: Ajax's drug binds to the inactive form of the JAK2 protein (a "Type II" approach), essentially flipping the off switch instead of wrestling with a spinning fan. Preclinical results look compelling, but Phase 1 data won't arrive until later this year. Lilly can afford the gamble; tirzepatide brought in $36.5 billion last year.
Why it matters: This is Lilly's latest move in a $20 billion-plus acquisition spree funded by GLP-1 profits, and it signals that big pharma sees differentiated hematology assets as worth betting billions on before human proof-of-concept even exists.
Read more →Gene Editing and Cell Therapy
The First In Vivo CRISPR Therapy Is Racing Toward the FDA
Intellia just reported the world's first Phase 3 results for an in vivo CRISPR therapy, and they're filing with the FDA in the second half of 2026. Their one-shot treatment for hereditary angioedema reduced attack rates by 96% in Phase 2, with 97% of patients staying attack-free for up to three years. If approved, it would be the first gene-editing therapy that works inside your body, no cell extraction required.
Read more →$110 Million Says CAR-T Can Finally Beat Solid Tumors
Every approved CAR-T therapy treats blood cancer. Zero have cracked solid tumors, which make up 90% of adult cancers. Shanghai-based Oricell just raised $110 million to change that, targeting liver cancer with a therapy that produced measurable tumor responses in every patient at the highest dose in Phase 1. Pivotal trials are next.
Read more →UCB Bets $1.15 Billion That Transplanted Brain Cells Can Stop Seizures
A 92% reduction in disabling seizures. That's what Neurona Therapeutics' brain cell therapy showed in early trials for drug-resistant epilepsy. UCB is paying up to $1.15 billion for the company, betting that injecting lab-grown neurons directly into the brain can replace destructive surgeries. Phase 3 dosing starts in the first half of 2026.
Read more →Deals and M&A
Gilead Drops $5 Billion on a Munich Startup to Fix Cancer's Guided Missile Problem
Antibody-drug conjugates are oncology's hottest drug class, but toxic payloads that leak early remain their Achilles' heel. Gilead is acquiring Tubulis for up to $5 billion because the German startup built a platform that locks cancer-killing payloads onto antibodies more tightly. It's Gilead's third major acquisition in three months, totaling over $14 billion.
Read more →Neurocrine Pays $2.9 Billion for the First Drug That Treats Prader-Willi Hunger
Prader-Willi syndrome causes relentless, life-threatening hunger with no off switch. Soleno's VYKAT XR is the first approved treatment, and it already pulled in $190 million in its launch year. Neurocrine is paying $2.9 billion (a 34% premium) to acquire Soleno, adding a third commercial product to diversify beyond its $2.5 billion tardive dyskinesia franchise.
Read more →Clinical and Regulatory
Lilly's Obesity Pill Got 1,390 Prescriptions in Week One. Cue the Panic.
Foundayo, Lilly's oral GLP-1 drug, logged just 1,390 prescriptions in its first week. Shares slid roughly 4–5% while rival Novo Nordisk climbed nearly 7%. But prescriptions nearly tripled to 3,707 by week two, and blockbuster drug launches almost never start with a bang. The real test comes when Lilly reports earnings on April 30.
Read more →The Kidney Drug That "Failed" Its Trial Just Got FDA Approval Anyway
Travere's Filspari missed its primary endpoint in the pivotal FSGS trial, which normally spells death for a drug program. But crushing secondary results (50% proteinuria reduction, double the remission rates of the comparator) and zero competing approved therapies convinced the FDA. It's now the first approved treatment for FSGS, a kidney disease affecting 40,000 Americans.
Read more →Funding and Markets
The Cancer Pathway Everyone Abandoned Just Got a $108 Million Revival
The AKT pathway has crushed more oncology drug programs than any other target. Terremoto Biosciences just raised $108 million to try again, using novel lysine-binding chemistry that hits AKT1 (the cancer driver) while sparing AKT2 (the one that causes brutal side effects). Their CEO previously built Mirati, which sold for $5.8 billion.
Read more →UK Biotech Raised Half a Billion Pounds in Q1. Zero Companies Went Public.
British biotechs pulled in 552 million pounds in Q1 2026, with venture capital up 17% quarter-over-quarter and 25 separate deals. Yet not a single UK biotech has IPO'd this year. The problem is structural: Nasdaq offers deeper pools and better valuations, so the best British companies keep listing in America instead.
Read more →